Cargando…

Treatment Choices Based on OncotypeDx in the Breast Oncology Care Setting

Introduction. This study aimed to evaluate whether OncotypeDx test results predict receipt of adjuvant chemotherapy in breast cancer patients who received an OncotypeDx recurrence score (RS). Materials and Methods. Pathology records were used to identify breast cancer patients who had OncotypeDx tes...

Descripción completa

Detalles Bibliográficos
Autores principales: Malo, Teri L., Lipkus, Isaac, Wilson, Tobi, Han, Hyo S., Acs, Geza, Vadaparampil, Susan T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3425834/
https://www.ncbi.nlm.nih.gov/pubmed/22927848
http://dx.doi.org/10.1155/2012/941495
_version_ 1782241424545153024
author Malo, Teri L.
Lipkus, Isaac
Wilson, Tobi
Han, Hyo S.
Acs, Geza
Vadaparampil, Susan T.
author_facet Malo, Teri L.
Lipkus, Isaac
Wilson, Tobi
Han, Hyo S.
Acs, Geza
Vadaparampil, Susan T.
author_sort Malo, Teri L.
collection PubMed
description Introduction. This study aimed to evaluate whether OncotypeDx test results predict receipt of adjuvant chemotherapy in breast cancer patients who received an OncotypeDx recurrence score (RS). Materials and Methods. Pathology records were used to identify breast cancer patients who had OncotypeDx testing between December 2004 and January 2009 (n = 118). Patient sociodemographic information, tumor characteristics, RS, and treatment-specific data were collected via chart review. RS was classified as follows: low (RS ≤ 17), intermediate (RS = 18–30), or high (RS ≥ 31). Bivariate analyses were conducted to investigate the relationship between adjuvant chemotherapy receipt and each sociodemographic and clinical characteristic; significant sociodemographic and clinical variables were included in a multivariable logistic regression model. Results. In multivariable analysis controlling for tumor size, histologic grade, and nuclear grade, only RS remained significantly associated with chemotherapy uptake. Relative to low RS, an intermediate (adjusted odds ratio [AOR], 21.24; 95% confidence interval [CI], 3.62–237.52) or high (AOR, 15.07; 95% CI, 1.28–288.21) RS was associated with a greater odds of chemotherapy uptake. Discussion. Results indicate that RS was significantly associated with adjuvant chemotherapy uptake, suggesting that OncotypeDx results were used to inform treatment decision making, although it is unclear if and how the information was conveyed to patients.
format Online
Article
Text
id pubmed-3425834
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-34258342012-08-27 Treatment Choices Based on OncotypeDx in the Breast Oncology Care Setting Malo, Teri L. Lipkus, Isaac Wilson, Tobi Han, Hyo S. Acs, Geza Vadaparampil, Susan T. J Cancer Epidemiol Research Article Introduction. This study aimed to evaluate whether OncotypeDx test results predict receipt of adjuvant chemotherapy in breast cancer patients who received an OncotypeDx recurrence score (RS). Materials and Methods. Pathology records were used to identify breast cancer patients who had OncotypeDx testing between December 2004 and January 2009 (n = 118). Patient sociodemographic information, tumor characteristics, RS, and treatment-specific data were collected via chart review. RS was classified as follows: low (RS ≤ 17), intermediate (RS = 18–30), or high (RS ≥ 31). Bivariate analyses were conducted to investigate the relationship between adjuvant chemotherapy receipt and each sociodemographic and clinical characteristic; significant sociodemographic and clinical variables were included in a multivariable logistic regression model. Results. In multivariable analysis controlling for tumor size, histologic grade, and nuclear grade, only RS remained significantly associated with chemotherapy uptake. Relative to low RS, an intermediate (adjusted odds ratio [AOR], 21.24; 95% confidence interval [CI], 3.62–237.52) or high (AOR, 15.07; 95% CI, 1.28–288.21) RS was associated with a greater odds of chemotherapy uptake. Discussion. Results indicate that RS was significantly associated with adjuvant chemotherapy uptake, suggesting that OncotypeDx results were used to inform treatment decision making, although it is unclear if and how the information was conveyed to patients. Hindawi Publishing Corporation 2012 2012-08-13 /pmc/articles/PMC3425834/ /pubmed/22927848 http://dx.doi.org/10.1155/2012/941495 Text en Copyright © 2012 Teri L. Malo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Malo, Teri L.
Lipkus, Isaac
Wilson, Tobi
Han, Hyo S.
Acs, Geza
Vadaparampil, Susan T.
Treatment Choices Based on OncotypeDx in the Breast Oncology Care Setting
title Treatment Choices Based on OncotypeDx in the Breast Oncology Care Setting
title_full Treatment Choices Based on OncotypeDx in the Breast Oncology Care Setting
title_fullStr Treatment Choices Based on OncotypeDx in the Breast Oncology Care Setting
title_full_unstemmed Treatment Choices Based on OncotypeDx in the Breast Oncology Care Setting
title_short Treatment Choices Based on OncotypeDx in the Breast Oncology Care Setting
title_sort treatment choices based on oncotypedx in the breast oncology care setting
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3425834/
https://www.ncbi.nlm.nih.gov/pubmed/22927848
http://dx.doi.org/10.1155/2012/941495
work_keys_str_mv AT maloteril treatmentchoicesbasedononcotypedxinthebreastoncologycaresetting
AT lipkusisaac treatmentchoicesbasedononcotypedxinthebreastoncologycaresetting
AT wilsontobi treatmentchoicesbasedononcotypedxinthebreastoncologycaresetting
AT hanhyos treatmentchoicesbasedononcotypedxinthebreastoncologycaresetting
AT acsgeza treatmentchoicesbasedononcotypedxinthebreastoncologycaresetting
AT vadaparampilsusant treatmentchoicesbasedononcotypedxinthebreastoncologycaresetting